Tilray (NASDAQ:TLRY) and Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.
This is a summary of recent recommendations for Tilray and Rock Creek Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rock Creek Pharmaceuticals||0||0||0||0||N/A|
Tilray presently has a consensus price target of $115.62, indicating a potential upside of 45.98%. Given Tilray’s higher probable upside, equities research analysts plainly believe Tilray is more favorable than Rock Creek Pharmaceuticals.
This table compares Tilray and Rock Creek Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rock Creek Pharmaceuticals||N/A||N/A||N/A|
Institutional and Insider Ownership
7.7% of Tilray shares are held by institutional investors. 0.9% of Rock Creek Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Tilray and Rock Creek Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tilray||$20.53 million||359.41||-$7.80 million||N/A||N/A|
|Rock Creek Pharmaceuticals||N/A||N/A||N/A||N/A||N/A|
Rock Creek Pharmaceuticals has lower revenue, but higher earnings than Tilray.
Tilray Company Profile
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.
Rock Creek Pharmaceuticals Company Profile
Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.